<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alfred K Cheung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles A Herzog, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients on dialysis are at extraordinarily high risk for death. In 2019, the estimated mortality rate of United States patients on dialysis was 173 deaths per 1000 patient-years, a figure that subsequently increased in 2020 in association with the coronavirus disease 2019 (COVID-19) pandemic [<a href="#rid1">1</a>].</p><p>As in the general population, the presence of cardiovascular disease (CVD) is an important predictor of mortality in patients with end-stage kidney disease (ESKD): CVD accounts for approximately 40 percent of deaths in patients on dialysis [<a href="#rid1">1</a>]. However, the relative prevalence of the various types of cardiac disease differs in patients on dialysis compared with the nondialysis population. Of CVD deaths in patients on dialysis, approximately 80 percent were presumably due to arrhythmic mechanisms; less than 10 percent could be attributed directly to coronary heart disease (CHD) (see  <a class="medical medical_review" href="/z/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a>). Nevertheless, the rate of death from myocardial infarction and the incidence of CHD are increased among patients on dialysis versus those without kidney disease. </p><p>This topic review will address the risk factors and epidemiology of CHD in patients on dialysis. The clinical manifestations, prevention, and treatment of CHD in these patients are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">"Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H3"><span class="h2">Traditional risk factors</span><span class="headingEndMark"> — </span>The difference in cardiovascular prognosis in patients on dialysis compared with those without kidney disease is related in part to the clinical status of patients when they initiate chronic dialysis [<a href="#rid2">2-5</a>]. Based upon the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study, a large percentage of incident patients on dialysis have traditional risk factors for cardiovascular disease (CVD) [<a href="#rid4">4</a>]. This includes diabetes (54 percent), low serum high-density lipoprotein (HDL) cholesterol levels (33 percent), hypertension (96 percent), left ventricular hypertrophy by electrocardiographic criteria (22 percent), low physical activity (80 percent), and increased age. It should be noted, however, that the influences of some of these traditional risk factors, such as hypertension, on CVD in patients on dialysis are less clear than in patients not on dialysis.</p><p>Many patients on dialysis have more than one of these risk factors, resulting in an even higher risk of adverse outcomes [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1848.html" rel="external">"Hypertension in patients on dialysis"</a>.)</p><p>Additional risk factors include the following [<a href="#rid7">7-12</a>] (see  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Dyslipidemia – Although most patients on dialysis have normal or even low serum total cholesterol levels, approximately 20 to 30 percent have serum total cholesterol levels greater than 240 mg/dL (6.2 mmol/L), while 10 to 45 percent have low-density lipoprotein (LDL) cholesterol levels greater than 130 mg/dL (3.4 mmol/L). In addition, hypertriglyceridemia, abnormalities in the composition and function of serum HDL particles, and elevated serum lipoprotein(a) levels are common in patients with chronic kidney disease (CKD) or end-stage kidney disease (ESKD). The CVD risks associated with specific serum lipid and lipoprotein levels in patients on dialysis is, however, not well understood. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical inactivity – Patients undergoing chronic dialysis are less active and perform at activity levels lower than those observed in sedentary healthy controls. The risk associated with low activity levels is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7324.html" rel="external">"Uremic myopathy and deconditioning in patients with chronic kidney disease (including those on dialysis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smoking – As noted in those without kidney disease, smoking is associated with a markedly increased risk of heart disease in patients on dialysis [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Risk factors unique to chronic kidney disease</span><span class="headingEndMark"> — </span>Some risk factors for atherosclerosis in patients with CKD result directly from the loss of kidney function and/or the utilization of measures aimed at replacing such function [<a href="#rid15">15</a>]. As examples:</p><p class="headingAnchor" id="H5"><span class="h3">Chronic kidney disease alone</span><span class="headingEndMark"> — </span>Several studies suggest that the presence of CKD per se, even when the decrease in glomerular filtration rate or the increase in albuminuria is modest, is an independent risk factor for the development of coronary heart disease (CHD). As a result, practice guidelines from the National Kidney Foundation and the American College of Cardiology/American Heart Association task force have recommended that CKD be considered a CHD risk equivalent [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Uremia and kidney replacement therapy</span><span class="headingEndMark"> — </span>Uremia and kidney replacement therapies result in markedly enhanced oxidant stress, the production of proinflammatory cytokines, increased adhesion molecules on endothelial cells, carbamylated proteins, and other proinflammatory factors [<a href="#rid19">19</a>]. These factors may provide the proper milieu for the development of accelerated atherosclerosis [<a href="#rid20">20-26</a>]. As an example, carbamylation of LDL, a process that occurs in uremia, is associated with multiple proatherogenic effects, including smooth muscle proliferation [<a href="#rid27">27</a>]. In part, this process also appears to underlie atherogenesis in patients who smoke [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1916.html" rel="external">"Uremic toxins"</a>.)</p><p>Whether peritoneal dialysis is associated with increased CVD risk compared with hemodialysis is unclear. The available evidence, though limited, suggests that CVD outcomes in patients on peritoneal dialysis are similar to those in patients on hemodialysis [<a href="#rid29">29,30</a>].</p><p>Inhibition of nitric oxide (NO) synthesis in those with ESKD may cause vasoconstriction and hypertension, thereby resulting in adverse cardiovascular outcomes. Asymmetrical dimethylarginine (ADMA), which is significantly increased in ESKD, is an endogenous inhibitor of NO [<a href="#rid31">31,32</a>]. Among patients on dialysis, ADMA may be a significant predictor of cardiovascular outcome and mortality [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Asymmetrical dimethylarginine'</a> and  <a class="medical medical_review" href="/z/d/html/1916.html" rel="external">"Uremic toxins"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Disorders of mineral metabolism</span><span class="headingEndMark"> — </span>Vascular calcification in patients on dialysis may be associated with abnormal bone and mineral metabolism. Deposition of calcium in arteries may occur in the intimal and medial layers (as observed in atherosclerotic plaques) or the medial layer alone. The latter is associated with stiffening of the vasculature but not atherosclerosis or luminal narrowing. Hence, vascular calcification in the ESKD setting may have different connotation from vascular calcification in the non-CKD population. (See  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease", section on 'Pathogenesis'</a>.)</p><p>Nonetheless, even without atherosclerosis or luminal narrowing, coronary medial calcification may cause decreased diastolic filling, and peripheral medial calcification increases afterload to the heart.</p><p>In patients on dialysis, increased intake of calcium-containing phosphate binders may directly enhance coronary arterial calcification. </p><p>Management approaches to bone metabolism and disease in CKD are presented elsewhere [<a href="#rid34">34,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Treatment approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Treatment goals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease", section on 'Initial treatment'</a>.)</p><p></p><p>A detailed discussion related to vascular calcification in patients with CKD is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence and prevalence of coronary heart disease (CHD) in the dialysis population depend in part upon the definition that is used [<a href="#rid36">36</a>]. A confounding issue is that coronary disease often presents in atypical fashion in patients on dialysis. As a result, the presence of CHD is frequently overlooked due to the absence of classic symptoms and/or signs of heart disease. Overall, the prevalence of CHD is much higher than that observed in the general population.</p><p>The 2022 Annual Data Report of the United States Renal Data System (USRDS) reported the following for patients on dialysis [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The unadjusted prevalence of CHD in 2020 was 43 and 37 percent among patients on hemodialysis and peritoneal dialysis, respectively  (<a class="graphic graphic_figure graphicRef143255" href="/z/d/graphic/143255.html" rel="external">figure 1</a>). For patients on hemodialysis, the prevalence of CHD was 22 percent among those ages 18 to 44 years and 41 percent among those ages 45 to 64 years. For patients on peritoneal dialysis, the prevalence of CHD was 18 percent among those ages 18 to 44 years and 35 percent among those ages 45 to 64 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2020, 16 percent of patients on hemodialysis and 13 percent of patients on peritoneal dialysis had a history of acute myocardial infarction  (<a class="graphic graphic_figure graphicRef143255" href="/z/d/graphic/143255.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2020, cardiac disease accounted for over 38 percent of all deaths in patients on hemodialysis. Of these cardiac deaths, only approximately seven percent were attributed to acute myocardial infarction and CHD, whereas over 80 percent were attributed to arrhythmia and cardiac arrest (which in many cases may be due to nonischemic etiologies such as myocardial fibrosis and left ventricular hypertrophy). However, CHD is a major risk factor for death among patients on dialysis: the unadjusted two-year mortality rate between 2017 and 2018 was 43 percent for patients on dialysis with CHD, compared with 23 percent in those without CHD [<a href="#rid37">37</a>]. </p><p></p><p>The incidence of CHD also varies by race among patients on dialysis. In a retrospective study, the incidence of new-onset atherosclerosis was 147 per 1000 person-years and 119 per 1000 person-years among White patients and Black patients, respectively, in the United States [<a href="#rid38">38</a>]. A similar, relatively lower incidence of myocardial infarction in Black patients was observed in a study using the USRDS database [<a href="#rid39">39</a>].</p><p>Occult and/or silent myocardial ischemia is also observed in a significant number of patients on dialysis [<a href="#rid2">2,13,40-43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one Japanese study, the presence of significant occult CHD (greater than 50 percent stenosis) using coronary angiography was found in 16 of 30 (53 percent) asymptomatic patients initiating kidney replacement therapy [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study of 67 asymptomatic patients, 28 (42 percent) had ≥50 percent stenosis in at least one vessel, while 19 (29 percent) had stenosis within the proximal third of an epicardial vessel [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third study of 67 patients on dialysis found that 16 (23 percent) demonstrated some evidence of silent ischemia during ambulatory Holter monitoring [<a href="#rid42">42</a>].</p><p></p><p>Silent ischemia is a concern clinically because it has been associated with an increased risk of myocardial infarction, serious arrhythmias, and sudden death in patients with and without end-stage kidney disease (ESKD). Several studies have confirmed a relationship between estimated glomerular filtration rate (eGFR) and the likelihood of developing chest pain with acute myocardial infarction [<a href="#rid45">45-48</a>]. As an example, one study that analyzed data from the USRDS and the third National Registry of Myocardial Infarction (NRMI 3) reported that only 44 percent of patients on dialysis reported chest pain with acute myocardial infarction, compared with 68 percent of patients not on dialysis [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">"Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traditional risk factors</strong> – A high percentage of patients undergoing maintenance dialysis have traditional risk factors for coronary heart disease (CHD), including diabetes, hypertension, left ventricular hypertrophy, dyslipidemia, increased age, smoking history, and physical inactivity. The effects of some of these traditional factors on CHD are less significant or less clear in the dialysis population than in the nondialysis population. (See <a class="local">'Traditional risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors unique to chronic kidney disease</strong> – Some other proposed risk factors for CHD, including uremic toxins, carbamylated proteins, dialysis therapy, abnormalities in mineral metabolism, and other factors are unique to those with kidney dysfunction. (See <a class="local">'Risk factors unique to chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The incidence and prevalence of coronary disease in the dialysis population depend in part upon the definition that is used. Overall, the burden of heart disease is much higher than that observed in the general population, although the precise contribution of CHD, in contrast to nonischemic heart disease, to cardiac mortality in the dialysis population is unclear. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="headingAnchor" id="H1821148117"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William Henrich, MD, MACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">United States Renal Data System. 2022 Annual data report. Available at: https://usrds-adr.niddk.nih.gov/2022 (Accessed on October 09, 2023).</li><li><a class="nounderline abstract_t">Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010; 55:S1.</a></li><li><a class="nounderline abstract_t">Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.</a></li><li><a class="nounderline abstract_t">Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13:1918.</a></li><li><a class="nounderline abstract_t">Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001; 38:537.</a></li><li><a class="nounderline abstract_t">Xue JL, Frazier ET, Herzog CA, Collins AJ. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005; 45:316.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606.</a></li><li><a class="nounderline abstract_t">Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999; 14:828.</a></li><li><a class="nounderline abstract_t">Herzog CA. Cardiovascular disease and dialysis patients: Is therapeutic nihilism justified. Semin Dial 1999; 12:285.</a></li><li><a class="nounderline abstract_t">Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:353.</a></li><li><a class="nounderline abstract_t">Dikow R, Adamczak M, Henriquez DE, Ritz E. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2002; :5.</a></li><li><a class="nounderline abstract_t">Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457.</a></li><li><a class="nounderline abstract_t">Di Benedetto A, Marcelli D, D'Andrea A, et al. Risk factors and underlying cardiovascular diseases in incident ESRD patients. J Nephrol 2005; 18:592.</a></li><li><a class="nounderline abstract_t">Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton) 2008; 13:667.</a></li><li><a class="nounderline abstract_t">McCullough PA. Coronary artery disease. Clin J Am Soc Nephrol 2007; 2:611.</a></li><li><a class="nounderline abstract_t">Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.</a></li><li><a class="nounderline abstract_t">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.</a></li><li><a class="nounderline abstract_t">van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.</a></li><li><a class="nounderline abstract_t">Hörl WH, Cohen JJ, Harrington JT, et al. Atherosclerosis and uremic retention solutes. Kidney Int 2004; 66:1719.</a></li><li><a class="nounderline abstract_t">Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8:475.</a></li><li><a class="nounderline abstract_t">Harper SJ, Bates DO. Endothelial permeability in uremia. Kidney Int Suppl 2003; :S41.</a></li><li><a class="nounderline abstract_t">Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14:1927.</a></li><li><a class="nounderline abstract_t">Buzello M, Törnig J, Faulhaber J, et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14:311.</a></li><li><a class="nounderline abstract_t">Bro S, Bentzon JF, Falk E, et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14:2466.</a></li><li><a class="nounderline abstract_t">Bro S, Moeller F, Andersen CB, et al. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 2004; 15:1495.</a></li><li><a class="nounderline abstract_t">Deicher R, Ziai F, Bieglmayer C, et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:1811.</a></li><li><a class="nounderline abstract_t">Ok E, Basnakian AG, Apostolov EO, et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68:173.</a></li><li><a class="nounderline abstract_t">Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13:1176.</a></li><li><a class="nounderline abstract_t">Van Biesen W, Vanholder R, Verbeke F, Lameire N. Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? Perit Dial Int 2006; 26:429.</a></li><li><a class="nounderline abstract_t">Lozier MR, Sanchez AM, Lee JJ, et al. Comparison of Cardiovascular Outcomes by Dialysis Modality: A Systematic Review and Meta-Analysis. Perit Dial Int 2019; 39:306.</a></li><li><a class="nounderline abstract_t">Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011; 58:93.</a></li><li><a class="nounderline abstract_t">Juonala M, Viikari JS, Alfthan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007; 116:1367.</a></li><li><a class="nounderline abstract_t">Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.</a></li><li class="breakAll">www.kidney.org/professionals/kdoqi/guidelines.cfm.</li><li class="breakAll">www.kdigo.org/clinical_practice_guidelines/kdigo_guideline_for_ckd-mbd.php.</li><li><a class="nounderline abstract_t">Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14:2556.</a></li><li class="breakAll">United States Renal Data System. 2020 Annual Data Report. https://adr.usrds.org/2020 (Accessed on November 16, 2020).</li><li><a class="nounderline abstract_t">Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: a sample of the US ESRD population. J Am Soc Nephrol 2005; 16:1420.</a></li><li><a class="nounderline abstract_t">Young BA, Rudser K, Kestenbaum B, et al. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. Kidney Int 2006; 69:1691.</a></li><li><a class="nounderline abstract_t">Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J 1990; 120:1073.</a></li><li><a class="nounderline abstract_t">Aronow WS, Ahn C, Mercando AD, Epstein S. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction. Am J Cardiol 1992; 69:137.</a></li><li><a class="nounderline abstract_t">Conlon PJ, Krucoff MW, Minda S, et al. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol 1998; 49:236.</a></li><li><a class="nounderline abstract_t">Charytan D, Kuntz RE, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 49:409.</a></li><li><a class="nounderline abstract_t">Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16:1141.</a></li><li><a class="nounderline abstract_t">Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010; 268:40.</a></li><li><a class="nounderline abstract_t">Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121:357.</a></li><li><a class="nounderline abstract_t">Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 2012; 163:399.</a></li><li><a class="nounderline abstract_t">Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116:1465.</a></li></ol></div><div id="topicVersionRevision">Topic 1960 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://usrds-adr.niddk.nih.gov/2022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : United States Renal Data System. 2022 Annual data report. Available at: https://usrds-adr.niddk.nih.gov/2022 (Accessed on October 09, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082919" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Excerpts from the US Renal Data System 2009 Annual Data Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856780" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089389" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532686" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685510" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of heart disease with diabetes and hypertension in patients with ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405218" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The clinical epidemiology of cardiac disease in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10328452" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiovascular disease in chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiovascular disease and dialysis patients: Is therapeutic nihilism justified</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886582" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982805" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Strategies to decrease cardiovascular mortality in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735083" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Increased serum lipoprotein(a) levels in patients with early renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16299687" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors and underlying cardiovascular diseases in incident ESRD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18761627" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699471" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859163" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289388" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307840" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458484" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Atherosclerosis and uremic retention solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071717" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694306" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Endothelial permeability in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819254" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538731" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514724" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153560" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814831" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954906" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17828273" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Protein carbamylation links inflammation, smoking, uremia and atherogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16881336" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296776" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of Cardiovascular Outcomes by Dialysis Modality: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518967" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724260" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514733" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514733" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788470" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: a sample of the US ESRD population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16598201" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2239659" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1729863" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9582554" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence and long-term significance of transient ST segment deviation in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336702" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743997" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210836" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065168" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424010" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785621" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
